You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Previously treated melanoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Melanoma Trial (Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice)

Not yet recruiting
  • Advanced Melanoma
  • (no location specified)
Sep 19, 2022

Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV Trial in Iowa City, Rochester, Madison ([212Pb]VMT01)

Not yet recruiting
  • Melanoma (Skin)
  • +5 more
  • Iowa City, Iowa
  • +2 more
Dec 8, 2022

Unresectable Cutaneous Melanoma, Metastatic Cutaneous Melanoma Trial in Worldwide (Sintilimab + IBI110)

Withdrawn
  • Unresectable Cutaneous Melanoma
  • Metastatic Cutaneous Melanoma
  • Sintilimab + IBI110
  • San Francisco, California
  • +12 more
Nov 16, 2022

Advanced Solid Tumor (Phase 1), Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous) Trial in United States (IMM-1-104)

Recruiting
  • Advanced Solid Tumor (Phase 1)
  • +4 more
  • Duarte, California
  • +4 more
Feb 2, 2023

Uveal Melanoma Trial in New York, Houston (Selumetinib)

Active, not recruiting
  • Uveal Melanoma
  • New York, New York
  • +2 more
Jun 28, 2022

Tumor, Solid, Pancreatic Cancer Trial in Chapel Hill (Ulixertinib, Palbociclib)

Recruiting
  • Tumor, Solid
  • +2 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Nov 30, 2022

Malignant Melanoma Stage III, Malignant Melanoma Stage IV Trial in Jette (TriMix-DC and ipilimumab)

Completed
  • Malignant Melanoma Stage III
  • Malignant Melanoma Stage IV
  • TriMix-DC and ipilimumab
  • Jette, Brabant, Belgium
    UZ Brussel
Mar 24, 2021

Melanoma, Metastatic Melanoma Trial in Boston (Ipilimumab, Nivolumab, Troriluzole)

Recruiting
  • Melanoma
  • Metastatic Melanoma
  • Boston, Massachusetts
  • +1 more
Sep 17, 2021

Metastatic Melanoma, Squamous Cell Skin Carcinoma Trial (Ad-MAGEA3, MG1-MAGEA3, Pembrolizumab)

Withdrawn
  • Metastatic Melanoma
  • Squamous Cell Skin Carcinoma
  • (no location specified)
Apr 1, 2021

Uveal Melanoma Trial in Pittsburgh (Tebentafusp)

Not yet recruiting
  • Uveal Melanoma
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Oct 5, 2023

Renal Cell Cancer, Melanoma, Non-Small-Cell Lung Cancer Trial in Duarte, Louisville, New York (PF-07263689, Sasanlimab)

Active, not recruiting
  • Renal Cell Cancer
  • +9 more
  • PF-07263689
  • Sasanlimab
  • Duarte, California
  • +5 more
Nov 8, 2022

Solid Tumor, Adult Trial in Shanghai (Tislelizumab, Lenvatinib, Cryoablation)

Recruiting
  • Solid Tumor, Adult
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Sep 13, 2023

Melanoma Trial in Beijing (tunlametinib, paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin)

Not yet recruiting
  • Melanoma
  • tunlametinib
  • paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Aug 15, 2023

Peri-implant Mucositis, Peri-Implantitis Trial in Pittsburgh (Induction of experimental peri-implant mucositis, Resolution of

Recruiting
  • Peri-implant Mucositis
  • Peri-Implantitis
  • Induction of experimental peri-implant mucositis
  • Resolution of experimental peri-implant mucositis
  • Pittsburgh, Pennsylvania
    University of Pittsburgh School of Dental Medicine
Sep 25, 2023

Pancreatic Ductal Adenocarcinoma, Pancreas Adenocarcinoma, Pancreas Cancer Trial in Kansas City (Enfortumab vedotin)

Recruiting
  • Pancreatic Ductal Adenocarcinoma
  • +2 more
  • Enfortumab vedotin
  • Kansas City, Kansas
    University of Kansas Cancer Center
Jun 23, 2023

Astrocytoma, Brain Cancer, Brain Metastases Trial in Kogarah, Liverpool (QBS10072S)

Recruiting
  • Astrocytoma
  • +22 more
  • Kogarah, New South Wales, Australia
  • +1 more
Apr 18, 2022

Metastatic Melanoma Trial in Marseille (PET with 18F-FDOPA)

Completed
  • Metastatic Melanoma
  • PET with 18F-FDOPA
  • Marseille, France
    Assistance Publique Hopitaux de Marseille
Nov 9, 2022

Solid Tumor Trial (IN10018, Nab-paclitaxel, Tislelizumab)

Not yet recruiting
  • Solid Tumor
  • (no location specified)
Aug 1, 2023

Colorectal Cancer Trial (ME-344, Bevacizumab)

Not yet recruiting
  • Colorectal Cancer
  • (no location specified)
Apr 20, 2023

Immunotherapy Among BRAF-Positive Melanoma Patients Treated in

Completed
  • Metastatic Melanoma
  • East Hanover, New Jersey
    Novartis Investigative Site
Nov 11, 2022

Soft Tissue Sarcoma Trial (ADI PEG20, Placebo)

Not yet recruiting
  • Soft Tissue Sarcoma
  • ADI PEG20
  • Placebo
  • (no location specified)
Jan 31, 2023

Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1

Not yet recruiting
  • Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
  • Ivosidenib 500mg
  • Placebo
  • (no location specified)
Nov 7, 2023

Long Term Efficacy and Safety Trial (Imlifidase administered in the 20-HMedIdeS-19 (PAES) study, Best available treatment

Not yet recruiting
  • Long Term Efficacy and Safety
  • Imlifidase administered in the 20-HMedIdeS-19 (PAES) study
  • Best available treatment administered in the 20-HMedIdeS-19 (PAES) study
  • (no location specified)
Jun 30, 2023

Colorectal Cancer Trial (Tislelizumab, Irinotecan Hydrochloride, cetuximab)

Not yet recruiting
  • Colorectal Cancer
  • (no location specified)
Mar 23, 2023

Primary Immune Thrombocytopenia (ITP) Trial (Ianalumab)

Not yet recruiting
  • Primary Immune Thrombocytopenia (ITP)
  • Ianalumab
  • (no location specified)
Jun 5, 2023